GlassScriptPhysician profile
Polina Liss
NPI 1225002009
$4,222.60
in general payments reported to CMS, 2019-2025
32 companies · $1,373 in 2025
The $1,373 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $226 · 2021: $90.08 · 2022: $174 · 2023: $651 · 2024: $981 · 2025: $1,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,941 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,940.77 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $606.49 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $505.66 | 2019-2024 | Xifaxan, Trulance |
| Amgen INC. | $429.56 | 2022-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.26 | 2024-2025 | Jardiance |
| Pfizer INC. | $235.67 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $194.76 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $177.56 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $175.77 | 2023-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $131.16 | 2022-2025 | Quviviq, Quviviq |
| Axsome Therapeutics, INC. | $125.66 | 2024-2025 | Auvelity |
| Novo Nordisk INC | $119.04 | 2019-2025 | Ozempic |
| Acella Pharmaceuticals, LLC | $107.66 | 2023-2025 | NP Thyroid 60 |
| Intra-Sana Laboratories | $100.56 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Kci USA, INC. | $96.34 | 2019 | |
| Radius Health, INC. | $96.08 | 2024-2025 | Tymlos, Binosto |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $94.18 | 2025 | Mounjaro, Zepbound, Jardiance |
| Ibsa Pharma INC. | $80.40 | 2019-2020 | |
| Bausch Health US, LLC | $67.91 | 2020-2025 | Wellbutrin, Aplenzin |
| Shire North American Group INC | $62.37 | 2019 | |
| Ucb, INC. | $56.99 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $56.11 | 2024 | |
| Eisai INC. | $50.35 | 2019 | |
| Currax Pharmaceuticals LLC | $49.96 | 2025 | Contrave |
| Phadia US INC. | $47.99 | 2022-2025 | Immunocap |
| Sanofi-Aventis U.S. LLC | $43.96 | 2024-2025 | |
| Amarin Pharma, INC. | $43.00 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $40.80 | 2019 | |
| Genentech USA, INC. | $30.20 | 2019 | |
| Almatica Pharma LLC | $24.53 | 2021 | |
| Celgene Corporation | $20.38 | 2019 | |
| Azurity Pharmaceuticals, INC. | $20.24 | 2023 | Adthyza |
| Lundbeck LLC | $20.00 | 2024 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Polina Liss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.